These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20848514)

  • 21. Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.
    Fenwick PS; Macedo P; Kilty IC; Barnes PJ; Donnelly LE
    PLoS One; 2015; 10(6):e0128757. PubMed ID: 26090665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Serum Level of CXCL9, CXCL10, and CXCL11 and the Expression of CXCR3 of Peripheral Blood Mononuclear Cells in Brucellosis Patients.
    Hassanshahi F; Noroozi Karimabad M; Miranzadeh E; Hassanshahi G; Torabizadeh SA; Jebali A
    Curr Microbiol; 2023 May; 80(6):201. PubMed ID: 37140634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication.
    Singh UP; Venkataraman C; Singh R; Lillard JW
    Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):111-23. PubMed ID: 17584151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis.
    Singh UP; Singh R; Singh S; Karls RK; Quinn FD; Taub DD; Lillard JW
    BMC Immunol; 2008 Jun; 9():25. PubMed ID: 18533024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs.
    Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H
    Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis.
    Hueso L; Ortega R; Selles F; Wu-Xiong NY; Ortega J; Civera M; Ascaso JF; Sanz MJ; Real JT; Piqueras L
    Int J Obes (Lond); 2018 Aug; 42(8):1406-1417. PubMed ID: 29795466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
    Müller M; Carter S; Hofer MJ; Campbell IL
    Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction.
    Manousou P; Kolios G; Drygiannakis I; Pyrovolaki K; Bourikas L; Papadaki HA; Kouroumalis E
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1823-33. PubMed ID: 18761554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis.
    Sun H; Fan J; Shang X; Tuohetaerbaike B; Li Y; Lv J; Wang Y; Wang L; Wang J; Ma X
    Life Sci; 2021 May; 272():119047. PubMed ID: 33454369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.
    Kouroumalis A; Nibbs RJ; Aptel H; Wright KL; Kolios G; Ward SG
    J Immunol; 2005 Oct; 175(8):5403-11. PubMed ID: 16210647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
    Trotta T; Costantini S; Colonna G
    Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A correlation study between gene polymorphism of Th cell expressed chemokine receptor CXCR3 and its ligand levels with HCV infection prognosis.
    Lu Y; Lin LY; Tan JG; Deng HP; Li XH; Zhang Z; Li Y; Zhou Z; Xu X; Xie X; Mei SJ
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1290-1295. PubMed ID: 28387899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.
    Koper OM; Kamińska J; Sawicki K; Kemona H
    Adv Clin Exp Med; 2018 Jun; 27(6):849-856. PubMed ID: 29893515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Common variants of chemokine receptor gene CXCR3 and its ligands CXCL10 and CXCL11 associated with vascular permeability of dengue infection in peninsular Malaysia.
    Hoh BP; Umi-Shakina H; Zuraihan Z; Zaiharina MZ; Rafidah-Hanim S; Mahiran M; Khairudin NY; Benedict LH; Masliza Z; Christopher KC; Sazaly AB
    Hum Immunol; 2015 Jun; 76(6):421-6. PubMed ID: 25858769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
    Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
    Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.
    Bedognetti D; Spivey TL; Zhao Y; Uccellini L; Tomei S; Dudley ME; Ascierto ML; De Giorgi V; Liu Q; Delogu LG; Sommariva M; Sertoli MR; Simon R; Wang E; Rosenberg SA; Marincola FM
    Br J Cancer; 2013 Oct; 109(9):2412-23. PubMed ID: 24129241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.
    Korniejewska A; McKnight AJ; Johnson Z; Watson ML; Ward SG
    Immunology; 2011 Apr; 132(4):503-15. PubMed ID: 21255008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease.
    D'Amato M; Bruce S; Bresso F; Zucchelli M; Ezer S; Pulkkinen V; Lindgren C; Astegiano M; Rizzetto M; Gionchetti P; Riegler G; Sostegni R; Daperno M; D'Alfonso S; Momigliano-Richiardi P; Torkvist L; Puolakkainen P; Lappalainen M; Paavola-Sakki P; Halme L; Farkkila M; Turunen U; Kontula K; Lofberg R; Pettersson S; Kere J
    Gastroenterology; 2007 Sep; 133(3):808-17. PubMed ID: 17854592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.
    Wang XX; Wang QQ; Wu JQ; Jiang M; Chen L; Zhang CF; Xiang LH
    Br J Dermatol; 2016 Jun; 174(6):1318-26. PubMed ID: 26801009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.